GlobeNewswire

Mitratech Strengthens Position in African Market with Union Systems Partnership

Dela

AUSTIN, Texas, March 15, 2018 (GLOBE NEWSWIRE) -- Mitratech, the leading provider of legal, compliance and risk management software announced today that it reached a partnership agreement with Union Systems Limited (USL), a leading information technology company specializing in the marketing and implementation of software solutions for banks and financial institutions across Africa. 

USL will market and implement Mitratech's DataStoreDSX Enterprise Content Management (ECM) software solution, which for over 20 years has been the industry standard ECM solution for banks in Africa with clients in every sub-Saharan country. This alliance strengthens both USL and Mitratech's position as the leading source of information governance and content management technology on a continent home to six of the world's ten fastest growing economies. With the increased ability to store, view, archive and distribute huge volumes of data regularly, DataStoreDSX helps banks comply with regulations including those frequently updated by Central Banks and various international regulatory bodies.      

"We have been supporting software at African banks for many years and we work with leading banks in different countries, so it is crucial for USL to engage with partners who can guarantee quality and bring a high level of expertise to our customers," said Aonghus GeraghtyPresident and Chief Sales Officer at Union Systems Limited.  "Digital technologies are characterized by large network effects, large fixed costs and close to zero marginal cost. At USL, we feel that these are key points for banks planning to be the big winners in the African market. Through our partnership with Mitratech, we will be able to help such ambitious banks fully automate their document handling across the entire bank, helping maintain regulatory compliance, reduce costs and improve customer service."

Over 25 banks, including the biggest bank in Africa and the most profitable bank in the continent's largest market, count on Mitratech to help them meet the increasing demand for customization, communications and access to customer information.  DataStoreDSX supports key enterprise processes and delivers end-to-end control of all content across an organization, including scanned documents, text files, images, word documents, emails, print streams, spreadsheets and more.  By providing a single source digital repository for structured and unstructured corporate information, DataStoreDSX integrates seamlessly with line of business applications to help manage information at an enterprise level and support an organization's immediate and future regulatory, legal, risk and operational requirements. 

"We are very excited to welcome Union Systems Limited to our partner network," added Connor Blake, Director of Alliances & Partnerships for Mitratech. "The combination of our DataStoreDSX document management solution, coupled with USL's expertise and long-term relationships with African banks, can only help further establish DataStoreDSX as the de facto standard for Enterprise Content Management in the region.  It delivers outstanding results by adapting to constantly changing operating conditions, regulations and competition." 

For more information on Mitratech, visit www.mitratech.com.  For more information on Union Systems Limited, visit www.unionsystems.com.

About Union Systems Limited
Union Systems Limited (USL) is an Information Technology Company focused on the support of advanced software for leading banks and financial institutions across Africa.  With headquarters in Lagos, Nigeria, the company has a deep understanding of the African markets.  Since the company was formed in 1993, USL has developed partnerships with international blue chip organisations including IBM, Oracle, Finastra, FircoSoft, 01 Systems and Mitratech.  To learn more, visit www.unionsystems.com 

About Mitratech
Mitratech is a market-leading provider of legal, compliance and risk software solutions for more than 1,200 organizations of all sizes across the globe, representing almost 40 percent of the Fortune 500, and over 500,000 users in over 160 countries. Mitratech's portfolio of enterprise legal and risk management software includes: legal matter management, spend management, eBilling, legal hold, contracts management, risk management, policy management, audit management and health & safety management. To learn more, visit www.mitratech.com.

MEDIA CONTACTS
Ellen Mason, Mitratech, ellen.mason@mitratech.com, +1.512.646.8802

Ngozi Ilondu, Union Systems Limited, ngozi.ilondu@unionsystems.com, +234.803.894.9461




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mitratech via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum